Patents by Inventor Carsten Münk

Carsten Münk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110294219
    Abstract: Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.
    Type: Application
    Filed: July 12, 2011
    Publication date: December 1, 2011
    Inventors: Martin Löchelt, Carsten Münk
  • Publication number: 20090202488
    Abstract: Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors.
    Type: Application
    Filed: June 6, 2005
    Publication date: August 13, 2009
    Applicant: DEUTSCHES KREBSFORSCHUNGCZENTRUM
    Inventors: Martin Löchelt, Carsten Münk
  • Patent number: 7312031
    Abstract: The present invention relates to the use of an alpha complementation assay as a quick, effective, and safe method for the detection of cell fusion mediated by viral proteins. Additionally, the method disclosed herein permits the identification of inhibitors of cell fusion using an alpha complementation assay.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: December 25, 2007
    Assignee: The Salk Institute for Biological Studies
    Inventors: Carsten Muenk, Anne Holland, Nathaniel Landau